Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2009

Open Access 01-12-2009 | Research article

The diagnostic role of glycosaminoglycans in pleural effusions: A pilot study

Authors: Rozina Vavetsi, Stefanos Bonovas, Paraskevi Polizou, Chrysanthi Papanastasopoulou, Georgia Dougekou, Nikolaos M Sitaras

Published in: BMC Pulmonary Medicine | Issue 1/2009

Login to get access

Abstract

Background

Pleural effusions are classified into transudates and exudates. Various criteria have been used with Light's et al being the most accepted ones. Glycosaminoglycans (GAGs) have been detected during pleural fluids (PF) analysis in various causes. In this pilot study, we investigated: (a) the usefulness of GAGs in the assessment of pleural effusions, and (b) whether and in what way GAGs correlate with established criteria used to indicate an exudate.

Methods

LDH, total protein, cholesterol and GAG levels were measured in pleural fluid and serum from 50 patients with pleural effusion. GAG levels were defined by the photometric method of Hata. The discriminative properties of pleural GAGs (pGAG), pleural fluid/serum GAG ratio (GAGR), serum GAGs (sGAG) and serum LDH (sLDH) were explored with ROC analysis.

Results

According to ROC analysis, pGAG and GAGR exhibited satisfactory discriminative properties in the separation of pleural effusions. For GAGR, at a 1.1 cut off point, sensitivity and specificity reached 75.6%; 95%CI: 60.5–87.1 and 100%; 95%CI: 47.8–100, respectively. For pGAG at a cut off value of 8.4 μg/ml, these percentages changed to 86.7%; 95%CI: 73.2–94.9 and 100%; 95%CI: 47.8–100. The study also revealed the differential role of sGAG between malignancies and benign cases, scoring 68.8%; 95%CI: 50.0–83.9 for sensitivity, and 84.6%; 95%CI: 54.5–97.6 for specificity at a 7.8 μg/ml cut off.

Conclusion

Our results suggest that glycosaminoglycan measurement of both serum and pleural effusions could be useful for simultaneous differentiation of exudates from transudates, and of malignant from benign exudates.
Appendix
Available only for authorised users
Literature
1.
go back to reference Light RW, Macgregor MI, Luchsinger PC: Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972, 77: 507-13.CrossRefPubMed Light RW, Macgregor MI, Luchsinger PC: Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972, 77: 507-13.CrossRefPubMed
2.
go back to reference Light RW: Useful tests on the pleural fluid in the management of patients with pleural effusions. Curr Opin Pulm Med. 1999, 5: 245-9. 10.1097/00063198-199907000-00012.CrossRefPubMed Light RW: Useful tests on the pleural fluid in the management of patients with pleural effusions. Curr Opin Pulm Med. 1999, 5: 245-9. 10.1097/00063198-199907000-00012.CrossRefPubMed
3.
go back to reference Hamm H, Bohmer R: Cholesterol in pleural effusions: a diagnostic aid. Chest. 1987, 92: 296-302. 10.1378/chest.92.2.296.CrossRefPubMed Hamm H, Bohmer R: Cholesterol in pleural effusions: a diagnostic aid. Chest. 1987, 92: 296-302. 10.1378/chest.92.2.296.CrossRefPubMed
4.
go back to reference Valdes L, Suarez J: Cholesterol: a useful parameter for distinguishing between pleural exudates and transudates. Chest. 1991, 99: 1097-102. 10.1378/chest.99.5.1097.CrossRefPubMed Valdes L, Suarez J: Cholesterol: a useful parameter for distinguishing between pleural exudates and transudates. Chest. 1991, 99: 1097-102. 10.1378/chest.99.5.1097.CrossRefPubMed
5.
go back to reference Roth BJ, O'Meara TF, Cragun WH: The serum-effusion albumin gradient in the evaluation of pleural effusions. Chest. 1990, 98: 546-9. 10.1378/chest.98.3.546.CrossRefPubMed Roth BJ, O'Meara TF, Cragun WH: The serum-effusion albumin gradient in the evaluation of pleural effusions. Chest. 1990, 98: 546-9. 10.1378/chest.98.3.546.CrossRefPubMed
6.
go back to reference Roboz J: Hyaluronic acid content of effusions as an aid for malignant mesothelioma. Cancer Res. 1985, 45: 1850-4.PubMed Roboz J: Hyaluronic acid content of effusions as an aid for malignant mesothelioma. Cancer Res. 1985, 45: 1850-4.PubMed
7.
go back to reference Soderblom T: High pleural fluid hyalorunan concentrations in rheumatoid arthritis. Eur Respir J. 1999, 13: 519-22. 10.1183/09031936.99.13351999.CrossRefPubMed Soderblom T: High pleural fluid hyalorunan concentrations in rheumatoid arthritis. Eur Respir J. 1999, 13: 519-22. 10.1183/09031936.99.13351999.CrossRefPubMed
8.
go back to reference Afify A, Lynne MC, Howell L: Correlation of Cytological Examination With Ellisa Assays for Hyaluronan and Soluble CD44v6 Levels in Evaluation of Effusions. Diagn Cytopathol. 2007, 35: 105-10. 10.1002/dc.20585.CrossRefPubMed Afify A, Lynne MC, Howell L: Correlation of Cytological Examination With Ellisa Assays for Hyaluronan and Soluble CD44v6 Levels in Evaluation of Effusions. Diagn Cytopathol. 2007, 35: 105-10. 10.1002/dc.20585.CrossRefPubMed
9.
go back to reference Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA: Cytological diagnosis of malignant mesothelioma-improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 2007, 450: 455-61. 10.1007/s00428-007-0375-x.CrossRefPubMed Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA: Cytological diagnosis of malignant mesothelioma-improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 2007, 450: 455-61. 10.1007/s00428-007-0375-x.CrossRefPubMed
10.
go back to reference Hata RI: Acidic glycosaminoglycans in urine, serum and myocardium of aged patients with myocardial infraction. J Mol Cell Cardiol. 1977, 9: 541-50. 10.1016/S0022-2828(77)80369-6.CrossRefPubMed Hata RI: Acidic glycosaminoglycans in urine, serum and myocardium of aged patients with myocardial infraction. J Mol Cell Cardiol. 1977, 9: 541-50. 10.1016/S0022-2828(77)80369-6.CrossRefPubMed
11.
go back to reference Bitter T: A modified uronic acid carbazole reaction. Anal Biochem. 1962, 4: 330-4. 10.1016/0003-2697(62)90095-7.CrossRefPubMed Bitter T: A modified uronic acid carbazole reaction. Anal Biochem. 1962, 4: 330-4. 10.1016/0003-2697(62)90095-7.CrossRefPubMed
12.
go back to reference Heffner JE, Brown LK, Barbieri CA, for the Primary Study Investigators: Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Chest. 1997, 111: 970-80. 10.1378/chest.111.4.970.CrossRefPubMed Heffner JE, Brown LK, Barbieri CA, for the Primary Study Investigators: Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Chest. 1997, 111: 970-80. 10.1378/chest.111.4.970.CrossRefPubMed
13.
go back to reference Bernard BD, Larock MP, Nguyen D, Corhay JL, Bury T, Hustinx R, Louis R: 18F-FDG PET imaging in assessing exudative pleural effusions. Nuclear Medicine Communications. 2006, 27: 971-6. 10.1097/01.mnm.0000243366.96012.c0.CrossRef Bernard BD, Larock MP, Nguyen D, Corhay JL, Bury T, Hustinx R, Louis R: 18F-FDG PET imaging in assessing exudative pleural effusions. Nuclear Medicine Communications. 2006, 27: 971-6. 10.1097/01.mnm.0000243366.96012.c0.CrossRef
Metadata
Title
The diagnostic role of glycosaminoglycans in pleural effusions: A pilot study
Authors
Rozina Vavetsi
Stefanos Bonovas
Paraskevi Polizou
Chrysanthi Papanastasopoulou
Georgia Dougekou
Nikolaos M Sitaras
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2009
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-9-9

Other articles of this Issue 1/2009

BMC Pulmonary Medicine 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.